CCR4 and neoplasm: While this anti-CCR4 mAb (mogamulizumab) therapy was intended to target Treg cells, particularly eTreg cells, which have the highest expression of CCR4, most patients who were treated with mogamulizumab did not exhibit tumor regression, as observed in our previous phase 1a study22.